Bio-techne CORP

Merck KGaA, Darmstadt, Germany, has entered into a definitive agreement to acquire Bio-Techne Corporation for $73 per share in cash.

Bio-Techne Corporation announced its third quarter fiscal year 2026 financial results, reporting a 2% decrease in revenue to $311.4 million, while also declaring a quarterly dividend of $0.08 per share.

Bio-Techne Corporation announces a key leadership transition, appointing Steve Crouse as President of its Diagnostics and Spatial Biology Segment, succeeding Dr. Matt McManus.

Bio-Techne Corporation announced flat revenue growth but increased GAAP and adjusted earnings per share for its second fiscal quarter ended December 31, 2025, alongside a quarterly cash dividend.

Bio-Techne Corporation announced its first quarter fiscal 2026 financial results, reporting a 1% revenue decrease and flat adjusted EPS, alongside the declaration of a $0.08 per share cash dividend.

Bio-Techne Corporation reported mixed fourth quarter and full-year fiscal 2025 results, highlighted by a strategic divestiture and strong adjusted earnings growth despite GAAP losses.

Bio-Techne Corporation's Q3 2026 results show a slight decrease in net sales and a dip in operating income, attributed to product mix and prior year non-recurring items.

Bio-Techne Corporation reports flat net sales for the quarter ended December 31, 2025, with diluted EPS increasing to $0.24, driven by cost management and divestitures.

Bio-Techne Corporation reported a 1% decrease in net sales to $286.6 million for the first quarter of fiscal 2026, yet saw net earnings climb to $38.2 million, driven by improved gross margins and strategic divestitures.

Bio-Techne Corporation reports a 4% increase in net sales but a decrease in net earnings for the third quarter of fiscal year 2025, primarily due to a non-recurring arbitration award.

Bio-Techne Corporation reports a 9% increase in net sales for the second quarter of fiscal year 2025, driven by strong performance in its Diagnostics and Spatial Biology segment and improving biopharma market conditions.

Bio-Techne Corporation saw a 5% increase in net sales but a decrease in net earnings for the quarter ended September 30, 2024, compared to the same period last year.

Bio-Techne Corporation reported a 5% increase in net sales to $1.2 billion for fiscal year 2025, but GAAP net earnings decreased 56% due to non-recurring charges, while adjusted net earnings grew 8%.

Bio-Techne Corporation's fiscal year 2024 saw a modest revenue increase alongside a significant drop in net earnings, influenced by acquisitions, strategic investments, and restructuring efforts.

James Hippel, CFO of BIO-TECHNE Corp, reported multiple transactions in common stock on July 29, 2026.

Kim Kelderman, Chief Executive Officer and a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on July 28, 2026.

Shane Bohnen, SVP - General Counsel of BIO-TECHNE Corp, reported multiple transactions in common stock on July 23, 2026.

Steven C. Crouse, President of Diagnostics & Spatial Biology at Bio-Techne, reported the vesting and sale of common stock.

Bio-Techne Corp. Director Amy E. Herr reported a sale of 6,636 shares of common stock on May 8, 2026, for approximately $48.28 per share.

CFO James Hippel exercised 62,000 stock options and subsequently withheld 56,955 shares to cover tax obligations.

BIO-TECHNE Corporation has filed definitive additional proxy soliciting materials with the U.S. Securities and Exchange Commission.

Bio-Techne Corporation reported 5% organic revenue growth and $1.2 billion in revenue for fiscal year 2025, alongside strategic portfolio adjustments and enhanced governance practices.

Bio-Techne Corporation has filed a definitive proxy statement with the SEC.

Bio-Techne's proxy statement highlights a CEO transition, strategic growth initiatives, and a focus on shareholder value amidst a challenging market environment.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 5.0% of Bio-Techne Corp's common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 11,559,571 shares, representing 7.38% of Bio-Techne Corp's common stock as of March 31, 2026.

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting a 2.2% beneficial ownership stake in BIO-TECHNE CORP common stock as of September 30, 2025.

T. Rowe Price Associates, Inc. has disclosed an increased beneficial ownership of 5.6% in Bio-Techne Corp.'s common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.0% beneficial ownership stake in BIO-TECHNE Corporation's common stock as of June 30, 2025.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 7.2% beneficial ownership stake in Bio-Techne Corp's common stock as of March 31, 2025.